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Differential expression of the 
protein kinase A subunits in normal 
adrenal glands and adrenocortical 
adenomas
Isabel Weigand1, Cristina L. Ronchi2, Marthe Rizk-Rabin3, Guido Di Dalmazi4, Vanessa Wild5, 
Kerstin Bathon6, Beatrice Rubin7, Davide Calebiro6, Felix Beuschlein  4, Jérôme Bertherat3, 
Martin Fassnacht1,2,8 & Silviu Sbiera1,2
Somatic mutations in protein kinase A catalytic α subunit (PRKACA) were found to be causative for 30–
40% of cortisol-producing adenomas (CPA) of the adrenal gland, rendering PKA signalling constitutively 
active. In its resting state, PKA is a stable and inactive heterotetramer, consisting of two catalytic and 
two regulatory subunits with the latter inhibiting PKA activity. The human genome encodes three 
different PKA catalytic subunits and four different regulatory subunits that are preferentially expressed 
in different organs. In normal adrenal glands all regulatory subunits are expressed, while CPA exhibit 
reduced protein levels of the regulatory subunit IIβ. In this study, we linked for the first time the loss 
of RIIβ protein levels to the PRKACA mutation status and found the down-regulation of RIIβ to arise 
post-transcriptionally. We further found the PKA subunit expression pattern of different tumours is also 
present in the zones of the normal adrenal cortex and demonstrate that the different PKA subunits have 
a differential expression pattern in each zone of the normal adrenal gland, indicating potential specific 
roles of these subunits in the regulation of different hormones secretion.
ACTH-independent Cushing syndrome is mostly due to cortisol-producing adrenocortical adenomas or carci-
nomas. Whereas adrenocortical cancer is a very rare tumour1, 2, adenomas with autonomous cortisol secretion 
are frequent3–5. With the advent of whole exome sequencing somatic mutations in the gene encoding the catalytic 
subunit α of protein kinase A (PRKACA) has been revealed in approximately 30–40% of CPA, associated with 
overt Cushing syndrome6–11. Also other components of cAMP/PKA signalling were often shown to be either 
mutated, such as the stimulating G protein (Gas) which is encoded by the GNAS gene or deregulated in different 
endocrine disorders12, 13 indicating the major role played by this pathway in hormonal secretion functions.
Under basal conditions, cAMP-dependent Protein Kinase (PKA) is a stable and inactive heterotetramer, con-
sisting of two catalytic and two regulatory subunits. The human genome encodes three different catalytic subunits 
(α, β and γ) and four different regulatory subunits (Iα, Iβ, IIα, IIβ) that are each preferentially expressed in dif-
ferent organs14. In addition, the protein kinase X was also shown to associate with the PKA regulatory subunits15. 
PKA has two isoforms, referred to as I and II, depending on whether type I or type II regulatory subunits bind the 
catalytic subunits16, 17. Common to all regulatory subunits is the inhibitory role of the activity of the PKA catalytic 
subunits in the absence of cAMP18. PKA signalling is activated when two molecules of cAMP bind each regula-
tory subunit of the PKA heterotetramer, leading to its dissociation and releasing of the catalytic subunits, which 
thereby become active. Furthermore, the regulatory subunits can specifically interact with A-kinase anchoring 
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proteins (AKAPs) that target PKA to specific subcellular compartments19, 20. This interaction may explain the 
different expression patterns and roles played by the different PKA isoforms.
Interestingly, the PRKACA mutations identified in CPA are situated at the interface between the catalytic 
subunit and the regulatory subunits6. By functional characterization of the initially identified L206R substitution 
and 199–200 insW insertion, it was shown that the binding of the regulatory subunits to the catalytic subunits is 
affected by these mutations, rendering PKA constitutively active21.
In normal adrenal glands (nAG), as in other endocrine tissues, both type I and II regulatory subunits are 
expressed22, but a detailed analysis had not been performed. Thus, it remains unclear if the expression of the 
regulatory subunits influences the specific steroidogenic profile of the three zones of the adrenal cortex. Of note, 
in some CPA, reduced protein levels of the regulatory subunit IIβ have been previously observed23, 24. Here we 
investigate if the PRKACA mutations leading to hyperactivity of PKA signalling in CPA are associated with the 
loss of RIIβ protein levels and demonstrate a clear connection between RIIβ protein levels and the mutation status 
of PRKACA. Furthermore, we describe a comprehensive pattern of PKA subunits expression in the different zones 
of the adrenal cortex and speculate about the functional consequences of these findings.
Material and Methods
Tissue collection. Formalin-fixed paraffin embedded (FFPE) tissues from patients that underwent surgery 
due to adrenocortical adenomas (n = 103) or carcinomas (n = 33) were consecutively collected at the University 
Hospitals of Wuerzburg (n = 115), Munich (n = 9) and Padua (n = 12). In addition, 15 FFPE tissues from normal 
adrenal glands from patients that underwent adrenalectomy due to kidney tumours were consecutively collected 
at the University Hospital Wuerzburg. Furthermore, fresh frozen tissues of 34 CPA were collected consecutively 
at the University Hospitals of Wuerzburg (n = 15) and Munich (n = 9), and the Hôpital Cochin Paris (n = 10)23 
for mRNA and protein analyses. All patients gave informed consent and the study was approved by the Ethics 
Comities of the University Hospitals of Wuerzburg, Munich and Padua and the Institute Cochin Paris. The 
PRKACA mutation status was determined using exome sequencing (CPACαmut n = 8, CPACαWT n = 13, (endocrine 
inactive adenomas = EIA n = 13)6, 11 or Sanger sequencing of the hotspot around the amino acid L206 (CPAmut 
n = 15, CPAWT n = 21) (some samples were also part of other studies6, 10). In addition, GNAS mutation status was 
determined using exome sequencing (CPAGNASmut n = 7, CPAGNASWT n = 26) or Sanger Sequencing of the hotspot 
region between amino acids R201 and Q227 (CPAGNASWT n = 5). The methods were carried out in accordance 
with the approved guidelines. Detailed patient and PRKACA mutation data of all CPA are listed in Supplementary 
Tables S1a and b.
Patients and clinical annotations. Clinical parameters, such as sex, age at diagnosis, tumour size, and 
laboratory hormone analysis, and in case of adrenocortical carcinoma (ACC), tumour stage according to the 
European Network for the Study of Adrenal Tumours (ENSAT) classification25, Weiss score, Ki67 index, presence 
and number of distant metastasis, and detailed follow-up information were collected through the German ACC 
and the ENSAT Registry (www.ensat.org/registry)26. Malignancy and hormonal hypersecretion were defined 
according to established clinical, biochemical, and morphological criteria. The patient characteristics are listed in 
the Supplementary Tables S1a,b and S2.
Chromogenic immunohistochemistry staining. Full FFPE slides were deparaffinised and antigen 
retrieval was performed in 10 mM citric acid monohydrate buffer (pH 6.5) in a pressure cooker for 13 min. 
Unspecific binding sites were blocked with 20% human AB serum at room temperature (RT) for 1 h and pri-
mary antibodies were incubated in an appropriate dilution concentration at RT for 1 h (PRKACA: BD #610980, 
1:1000; PRKAR2B: Sigma #HPA008421, 1:40; PRKAR1A: Novus #29250002, 1:250; PRKAR1B: Abnova 
#H00005575-M05, 1:100; PRKAR2A: BD #612243, 1:5000 and N-Universal Negative Controls anti-rabbit or 
anti-mouse: Dako). Signal amplification was achieved by En-Vision System Labelled Polymer-HRP Anti-Rabbit 
(Dako) for 40 min and developed for 10 min with DAB+ Liquid Kit (Dako). Nuclei were counterstained using 
Mayer’s hematoxylin for 2 min. Specificities of antibodies were determined by WB. All antibodies gave one spe-
cific band at the predicted size.
Quantitative analysis of PKA subunits immunoreactivity. Chromogenic staining intensities were 
determined by two independent investigators (I.W. & S.S.) and graded as 0 (negative), 1 (low), 2 (medium) and 3 
(high). The proportion of positive tumour cells was calculated for each specimen and scored 0 if 0% were positive, 
0.1 if 1–9% were positive, 0.5 if 10–49% were positive and 1 if 50% or more were positive27, 28. A semi quantitative 
H-score was then calculated by multiplying the staining intensity grading score with the proportion score as 
described previously29. Where discrepancies were observed, results were jointly assessed by both investigators 
and the final score was formed by consensus. The Spearman r for inter-observer agreement for each staining was 
high (>0.85).
Fluorescence immunohistochemistry staining. Full FFPE slides were deparaffinised and antigen 
retrieval was performed as described in the previous chapter. Unspecific binding sites were blocked with 20% 
human AB serum in TBS and to reduce auto fluorescence, cold water fish skin gelatine (Aurion) was added to 
a final concentration of 0.1% to the blocking buffer and incubated at RT for 30 min. Primary antibodies were 
incubated in an appropriate dilution concentration overnight at 4 °C (PRKAR2B: Sigma #HPA008421, 1:30; 58K 
Golgi protein: GeneTex #GTX26284, 1:50). Fluorescence labelled secondary antibodies against rabbit (goat-anti 
rabbit-Alexa596; LifeTechnologies #A11072, 1:200) and mouse (goat anti mouse-Alexa488; Dianova #115-545-
062, 1:200) were used at RT for 3 h. Vectashield with DAPI (Vector Laboratories #H1200) was used as nuclear 
counterstain and mounting medium. Optical images were acquired using a Leica SP5 confocal microscope.
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Gene expression analysis. RNA from fresh frozen tissues was isolated using the RNeasy Lipid Tissue 
Mini Kit (Qiagen) and reverse transcribed with the QuantiTect Reverse Transcription Kit (Qiagen). qRT-PCR 
was performed using pre-designed Taqman gene expression probes (Thermo Fischer Scientific) for PRKACA 
(Hs00427274_m1) and all PKA regulatory subunits (PRRKAR1A: Hs00267597_m1, PRKAR2A: Hs00177760_m1; 
PRKAR1B: Hs00406762_m1; PRKAR2B: Hs00176966_m1). Endogenously expressed β-actin (Hs9999903_m1) 
was used for normalization. 5 ng cDNA were used for each PCR reaction and each sample was analysed in dupli-
cate. Transcripts were amplified using the TaqMan Gene Expression Master Mix (Thermo Fischer), the CFX96 
real-time thermocycler (Bio-rad) and Bio-Rad CFX Manager 2.0 software. Cycling conditions were 95 °C for 
three min followed by 50 cycles of 95 °C for 30 sec, 60 °C for 30 sec, and 72 °C for 30 sec. Using the ΔCT method30, 
the gene expression levels were normalized to those of β-actin.
Western blot analysis. 20 mg of tumour tissue were shredded in lysis buffer containing 1% Triton-X and 
protease inhibitors. After sonication, cells were frozen at −80 °C, thawed and protein concentrations were deter-
mined using a bicinchoninic acid (BCA) kit (Sigma-Aldrich).
12 µg protein from each sample was loaded on a 10% denaturing gel and proteins were separated by 
SDS-PAGE31. Proteins were transferred by tank blot onto a PVDF Membrane (GE Healthcare) and membranes 
were blocked in 5% skimmed milk in TBS-Tween at RT for 1 h. Primary antibodies (PRKAR2B: BD #610625, 
1:1000 and PRKACA: BD #610980, 1:1000) were incubated over night at 4 °C. Membranes were washed 3 times 
in TBS-Tween and HRP-labelled secondary antibodies (goat-anti rabbit: Jackson ImmunoResearch Laboratories, 
#111-035-144 and goat-anti mouse: Jackson ImmunoResearch Laboratories, #115-035-003) were diluted 1:10000 
and incubated at RT for 1 h. The protein-antibody complex was visualized by enhanced chemiluminescence using 
the Amersham ECL Prime reagent (GE Healthcare) and documented on X-ray film (Fuji). Normalization of pro-
tein levels was performed by re-probing the blot with an antibody recognizing human GAPDH (Sigma-Aldrich 
1:10000). Autoradiographs were scanned, and the quantification of individual bands was performed using the 
FIJI software32.
Statistical analysis. The Mann-Whitney- U test was used to determine differences between two 
non-parametric datasets and Kruskal-Wallis test with Dunns post-test were used to determine statistically sig-
nificant differences between more than two non-parametric datasets. Statistical analyses were performed using 
GraphPad Prism (version 6.0). P values < 0.05 were considered as statistically significant.
Results
RIIβ and RIα protein levels are significantly decreased in Cα-mutated CPA. Chromogenic immu-
nohistochemistry staining on FFPE tissue from CPA (with mutated (n = 18) and WT (n = 20) PRKACA), aldos-
terone producing adenoma = APA (n = 20), EIA (n = 25) and ACC (n = 33) was performed for all PKA regulatory 
subunits and the catalytic subunit α. While Cα protein levels were not altered between PRKACAmut CPA (Fig. 1A) 
and PRKACAwt CPA (Fig. 1B), CPAs in general had lower Cα protein levels compared to the other tumour types 
(Fig. 1C). RIα had significantly decreased immunoreactivity in PRKACAmut CPA (Fig. 1D) compared to a strong 
immunoreactivity in PRKACAwt CPA (Fig. 1E). Overall, RIα protein levels were very high in adrenocortical 
tumours (Fig. 1F).
We did not observe any significant differences in protein levels between PRKACAwt and PRKACAmut CPA 
for the regulatory subunits IIα and Iβ (mean intensity 1.91 ± 0.67 vs 1.42 ± 0.91, p = 0.13 and 1.78 ± 0.79 vs 
1.53 ± 0.79, p = 0.05, respectively) (Fig. 1G–L). However, RIIβ showed no or very weak immunoreactivity in 
PRKACAmut CPA, while staining intensity was significantly higher in PRKACAwt CPA (0.42 ± 0.48 vs 1.55 ± 0,72, 
p < 0.05) (Fig. 1M,N). A few PRKACA mutated samples showed a strong or normal expression of RIIβ, but they 
did not harbour the most common, L206R mutation, but other mutations in PRKACA (p.E32V: green, p.245_248.
del: red, see Fig. 1 legend). Between the different endocrine active adenomas, the strongest staining intensity of 
RIIβ was observed in APA (2.53 ± 0.90 vs 0.42 ± 0.48 vs 1.55 vs 0.72, p < 0.05) (Fig. 1O).
Strongly reduced RIIβ protein levels in Cα-mutated CPA compared to WT CPA were further confirmed 
by Western blot analysis from three different patient cohorts including 2 cohorts from Germany and one from 
France (Fig. 2A) (RIIβ to GAPDH ratio in PRKACAmut CPA vs PRKACAwt CPA: 0.08 ± 0.12 vs 0.86 ± 0.53, 
p < 0.0001) (Fig. 2B). In general, all PRKACA mutated samples showed only weak expression of RIIβ. The only 
exception was the recently detected p.245_248del mutation, which was found in a patient with autonomous cor-
tisol secretion but no overt Cushing syndrome (upper blot). Also Cα protein levels were reduced in mutated 
compared to WT samples although not to the same extent (Fig. 2B). Since approximately 10% of CPA harbour 
activating somatic mutations in the GNAS gene, leading to increased PKA signalling7–9, we investigated if GNAS 
mutations also affect the stability of PKA regulatory subunits. For this purpose, we analysed additionally the 
CPA GNAS mut separately from CPA PRKACA mut and CPA PRKACA WT GNAS WT both regarding immunohistochemistry 
and immunoblotting results. However, mutations in the GNAS gene did not point to any degradation of the PKA 
regulatory subunits in CPA (Supplementary Fig. 1).
mRNA expression of PKA subunits is not significantly altered between Cα-mutated CPA and 
WT CPA. To explore if the Cα mutations have an effect on the transcriptional regulation of any PKA subunit, 
we performed qRT-PCR. mRNA expression levels were not altered between the PRKACAmut and PRKACAwt CPA 
for all the PKA subunits we tested (Fig. 3), but Cα expression was increased, while RIα and RIIβ expressions 
were decreased in all CPA compared to nAG (0.16 ± 0.07 vs 0.07 ± 0.04, p = 0.0033; 4.81 ± 4.44 vs 11.12 ± 2.15, 
p = 0.0003 and 0.42 ± 0.35 vs 1.07 ± 0.22, p = 0.001, Fig. 3A,B,E, respectively).
RIIβ localizes to the Golgi apparatus in PRKACAWT tumour cells and is not detectable in 
PRKACAL206R mut cells. In order to investigate, a possible connection between reduced RIIβ protein levels 
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in PRKACA mutated tumours and its subcellular localization in these tumours, we performed simultaneous flu-
orescence immunohistochemistry of RIIβ and the Golgi apparatus in a subset of 10 CPA (6 WT and 4 mutated). 
Figure 1. Immunhistochemical staining of the PKA subunits on CPA. Representative immunohistochemical 
staining for the PKA Cα subunit in CPA PRKACAmut (A) and CPA PRKACAWT (B). An analysis of all stained tissues 
for Cα is shown in (C). Representative immunohistochemical staining for the PKA RIα subunit in CPAmut (D) 
and CPAWT (E). An analysis of all stained tissues for RIα is shown in (F). Representative immunohistochemical 
staining for the PKA RIβ subunit in CPAmut (G) and CPAWT (H). An analysis of all stained tissues for RIβ is 
shown in (I). Representative immunohistochemical staining for the PKA RIIα subunit in CPAmut (J) and 
CPAWT (K). An analysis of all stained tissues for RIIα is shown in (L). Representative immunohistochemical 
staining for the PKA RIIβ subunit in CPAmu (M) and CPAWT (N). An analysis of all stained tissues for RIIβ is 
shown in (O). Mutations, other than the L206R mutation are indicated in different colours. p.200_201insV: 
blue, p.199_200insW: grey, p.E32V: green, pW197R: orange, p.245_248.del: red. Kruskal-Wallis test with Dunn’s 
correction for multiple comparisons was performed to determine statistically significant differences between all 
data sets. *p < 0.05.
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Co-staining of RIIβ and several different organelle markers in adrenocortical tumour cells NCI-H295R, revealed 
a co-localization of RIIβ with the Golgi apparatus but not with the endoplasmic reticulum, mitochondria or lyso-
somes (Supplementary Material & Methods; Supplementary Fig. 2). And indeed, in our stained PRKACAWT CPA 
tissues, RIIβ had a very localized distribution, accumulating in small spots close to the nucleus (Fig. 4A). Golgi 
apparatus staining showed a very similar pattern and the overlay revealed a close proximity of RIIβ and Golgi 
apparatus (Fig. 4A,B). In PRKACAL206Rmut CPA, RIIβ staining was not detectable and there was no indication that 
it changed location in these cells (Fig. 4C).
The PKA subunits are differentially expressed in normal adrenal glands. The above mentioned 
observations that the different PKA subunits have different expression patterns between the tumours with differ-
ent hormonal pattern suggest some relation between PKA subunit expression and steroid secretion. Therefore, 
we analysed expression levels of these subunits in the different zones of the adrenal cortex and the medulla. Cα 
protein levels were highest in the zona glomerulosa, but it was also moderately strong expressed in the other two 
zones of the cortex and was almost absent in the medulla (Fig. 5). In general, expression of all subunits was rather 
low in the medulla with exception of RIIα, which in contrast to all other subunits was almost ubiquitously strong 
throughout the adrenal gland (RIα: 0.71 ± 0.49; RIIα: 3.0 ± 0.0; RIβ: 0.0 ± 0.0; RIIβ: 0.67 ± 0.58; Cα: 0.50 ± 0.71) 
(Fig. 5E). The zona glomerulosa seems to be characterized by low expression of RIβ, whereas all other subunits 
are rather highly expressed (RIα: 3.0 ± 0.0; RIIα: 2.67 ± 0.62; RIβ: 0.71 ± 0.61; RIIβ: 2.82 ± 0.40; Cα: 2.71 ± 0.47) 
(Fig. 5). The pattern in the cortisol-producing zona fasciculata is strikingly similar with one exception, the low 
expression of RIIβ (RIα: 2.89 ± 0.33; RIIα: 2.13 ± 0.83; RIβ: 0.71 ± 0.61; RIIβ: 1.18 ± 0.60; Cα: 1.79 ± 0.89) 
(Fig. 5B). Thus, the two β subunits seem to be negatively correlated with secretion of aldosterone and cortisol, 
a pattern which can also be partly found in the aldosterone- and cortisol-producing adenomas. Interestingly, 
the zona reticularis, which produces quantitatively the highest amount of steroid hormones in the circulating 
blood, mainly precursors and androgen, is characterized by high expression of all four regulatory subunits (RIα: 
2.67 ± 0.5; RIIα 2.53 ± 0.64; RIβ: 2.64 ± 0.5; RIIβ: 2.18 ± 0.87; Cα: 1.71 ± 0.83) (Fig. 5).
Discussion
Decreased protein levels of PKA RIIβ and RIα subunits in cortisol producing adenomas. In 
2008 two studies had shown that protein expression of the RIIβ subunit of PKA is markedly reduced in CPA 
compared to other adrenocortical tumours, while no such differences were observed regarding the expression 
of the other regulatory subunits23, 24. There were some discrepancies between the two studies, with Mantovani 
et al. demonstrating that a loss of RIIβ results in a compensatory increase of RIα protein levels in Y1 cells, while 
Vincent-Dejean et al. failed to observe this phenomenon in tumour samples. Furthermore, the latter found 
decreased RIIβ protein levels only in a subpopulation of CPA with increased PKA activity. This discrepancy came 
Figure 2. Western blots of cortisol producing adrenocortical adenomas. Western blotting of RIIβ, Cα and 
GAPDH. The patient ID according to Supplementary Tables S1a and b are given under each band. PRKACA 
mutation status is indicated as such and “*” indicates samples harbouring the L206R mutation in PRKACA, 
as well (A). Densiometric analysis of western blots was done using the Fiji software32. The quotient of RIIβ/
GAPDH and Cα/GAPDH was normalized to the mean of WT RIIβ GAPDH or Cα/GAPDH and this ratio is 
shown on the y-axis (B).
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as a surprise, as the compensatory up-regulation of one regulatory PKA subunit in response to down-regulation 
of the other has been shown in several systems33, 34. One study demonstrated that also mutations in the regulatory 
subunit RIα, leading to its decreased expression, induced the compensatory mechanism leading to an increase of 
other regulatory subunits34. The down-regulation of RIIβ in CPA could not be explained for some time. Recently, 
we could prove that mutations in the Cα subunit decrease the binding potential of regulatory subunits21 and 
already many years ago it was demonstrated, that unbound regulatory subunits are normally degraded in the pro-
teasome in a ubiquitin-dependent manner35. Following the discovery of mutations in the gene encoding for the 
catalytic subunit α of PKA as the underlying cause of CPA tumourigenesis6 we hypothesized that these mutations 
might be causative for the decreased RIIβ protein expression in these tumours. Therefore, we assessed the protein 
levels of PKA subunits by both immunohistochemistry and immunoblotting in a large series of adrenocortical 
Figure 3. PKA subunits mRNA expression on CPA. Relative PKA subunits mRNA expression (normalized 
to β-actin using the ΔCT method30) for PRKACA (A), PRKAR1A (B), PRKAR2A (C), PRKAR1B (D) and 
PRKAR2B (E). The non-parametric Mann-Whitney-U Test was performed to identify statistical differences 
between CPA (combined CPA PRKACA mutated and non mutated) and normal adrenal glands (nAG). Red dot: 
p.245_248del mutation in PRKACA, blue dot: p.W197R PRKACA mutation.
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tumours with known PRKACA mutation status, including 10 samples that had already been included in the study 
by Vincent-Dejean et al.23.
Since reduced RIIβ protein levels were found in CPA in general24 but were particularly pronounced in a sub-
population of CPA with high PKA activity23, we hypothesized, that this subpopulation is the PRKACA mutated 
CPA group. This hypothesis was confirmed by our immunohistochemistry results where CPA with mutations 
in the PRKACA gene showed reduced RIIβ protein levels compared to PRKACAwt CPA. We also observed sig-
nificantly reduced RIα protein levels in PRKACAmut compared to PRKACAwt CPA but no significant differences 
concerning the other two regulatory subunits or the catalytic subunit itself. One possible explanation for this 
down-regulation could be the general differences in abundance of these two regulatory subunits in the adrenal 
cortex, so the degradation of unbound regulatory subunits failing to bind the mutated catalytic subunits may be 
stronger in the case of the subunits with higher adrenal expression.
Surprisingly, the only PRKACAwt CPA that lacked immunoreactivity for RIIβ in immunohistochemistry was 
from a patient with autonomous cortisol secretion and did not reveal any somatic mutations affecting the cAMP/
PKA signalling pathway. Interestingly, in this sample, by whole exome sequencing, we could identify a germline 
genomic variant in the GNAS gene (encoding the alpha subunit of the stimulatory G protein (Gs) and involved 
in cAMP regulation) (p.R600G, SNP: rs74897360)11, however, the clinical significance of this SNP has never been 
investigated before.
Mantovani et al. found decreased RIIβ protein levels in CPA compared to ACC24. In our series only the 
PRKACAmut CPA had significantly decreased RIIβ levels compared to ACC but not WT CPA. Neither did we 
observe any significant differences between the other PKA subunits between any of the adrenocortical adenomas 
subgroups, nor when we compared them with adrenocortical carcinomas. This previous study also showed that 
in the low RIIβ group there was also a significant reduction in RIIα protein and a tendency for reduced Cα and 
Figure 4. Co-immunofluorescence of RIIβ and the Golgi apparatus. Representative co-immunofluorescence 
of RIIβ (magenta) and the Golgi marker 58K protein (green) in a PRKACAWT tumour (A,B) and in an 
PRKACAL206R mut tumour (C). The overview shows accumulation of RIIβ in localized areas close to the nucleus 
and the overlay with the Golgi apparatus marker reveals co-localization (white, arrowheads). A higher 
magnification of the same tumour shows the close proximity of RIIβ and the Golgi apparatus (B), while the RIIβ 
staining is absent in the L206R mutated tumour (C). Scale bar 20 µm (A) and 10 µm (B,C).
www.nature.com/scientificreports/
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RIα subunits protein expression. Although we did not investigate RIIα with immunoblotting, we did not observe 
reduced RIIα protein levels in PRKACAmut CPA by immunohistochemistry. However, what we could show was 
that the Cα and RIα protein levels were both significantly reduced in PRKACAmut compared to PRKACAwt CPA. 
The discrepancy between these results and the fact that immunohistochemistry did not reveal a similar reduction 
for the Cα could arise from partly different samples and also from the two methods used. But also other groups 
found a reduced expression of the mutant Cα protein8 in the tumours.
In contrast to the samples carrying the frequent L206R PRKACA mutations, decrease of RIIβ protein levels 
was observed in only some of the other mutated tumours. Highest RIIβ expression was observed in the sample 
carrying the p.E32V mutation11, which lies outside the interface of regulatory and catalytic subunits and does 
maybe not influence the formation of a stable PKA holoenzyme. Unchanged RIIβ protein expression in western 
blot analysis was also found in the sample carrying the p.245_248.del mutation11, however, this tumour is from 
a patient without signs of clinical Cushing Syndrome, suggesting that the effects of this mutation are less severe.
Figure 5. Immunohistochemical staining of the PKA subunits in normal adrenal glands. Representative 
immunohistochemical staining of the PKA subunits in the different zones of the adult normal adrenal 
gland and analysis of staining intensities of the different zones of the adrenal cortex and the medulla. Cα is 
strongly expressed in the Zona glomerulosa (A), RIIβ is strongly expressed in the Zona glomerulosa and Zona 
reticularis (B), RIα is strongly expressed in all zones of the adrenal cortex (C), RIβ has a strong expression in 
the Zona reticularis (D) and RIIα is expressed in the whole adrenal gland including the medulla (E). ZG: Zona 
glomerulosa, ZF: Zona fasciculata, ZR: Zona reticularis. Kruskal-Wallis test with Dunn’s correction for multiple 
comparisons was performed to determine statistically significant differences between all data sets. *p < 0.05, 
**p < 0.01, ***p < 0.001.
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As at mRNA level, we did not observe any downregulation of RIα and RIIβ in PRKACAmut samples compared 
to PRKACAwt CPA, therefore a post-translational regulation and/or degradation is a more likely explanation for 
the decrease in protein levels. In 2011, it was shown that the E3 ligase Praja2 interacts with the regulatory subunits 
Iα, IIα and IIβ, tagging them for proteasomal degradation in order to prolong the activated PKA signalling36. 
However, our results indicate a more restricted mechanism of degradation, especially for RIIβ in PRKACAmut 
samples, since RIIβ protein levels were completely absent in most samples. This degradation could be mediated by 
a RIIβ-specific A-kinase anchoring protein (AKAP), that modifies either its subcellular localization or tags it for 
proteasomal/lysosomal degradation. Indicative for such a degradation tagging would be the change of RIIβ pro-
tein localization between PRKACAwt and PRKACAmut samples towards a more proteasomal/lysosomal localiza-
tion. As we hypothesized that the PRKACA mutations possibly changes RIIβ subcellular localization we checked if 
RIIβ is also co-localized with the golgi apparatus in tissues derived from PRKACAwt and PRKACAL206Rmut CPA or 
if this localization changes in the mutated samples. A co-localization of RIIβ with the Golgi apparatus has already 
been described in different cell types37, 38. This hypothesis proved not to be true so we don’t have yet a conclusive 
answer for the reasons leading to low levels of RIIβ in PRKACAL206Rmut CPA. Now, additional functional studies 
would be necessary to answer this question but they are beyond the scope of this publication.
Interestingly, other groups investigating the expression of the PKA subunits in other endocrine tissues such 
as thyroid and thyroid derived tumours39 found exactly the opposite, no to low levels of RIIβ and RIα in normal 
thyroid tissue but both subunits had increased levels in both benign and malignant thyroid tumours39 showing 
that PKA function in endocrine organs is very variable.
Possible correlation between expression of different PKA subunits and hormone secretion pat-
tern in normal adrenal glands. A differential expression of several PKA isoforms in different tissues or 
subcellular compartments has already been described14, 38. Here we have demonstrated further, that some PKA 
subunits are not only organ specific, but that their expression is different between the different functional zones 
of the adrenal cortex, indicating possible specific roles in the secretion of hormones. The catalytic subunit α is 
most abundantly expressed in the zona glomerulosa, the zone of the adrenal cortex that secretes mainly miner-
alcorticoids. However, the strong expression of Cα seems to be compensated by a strong expression of all regu-
latory subunits, with the exception of RIβ, in this zone, suggesting a high level of regulation through formation 
of an inactive PKA heterotetramer. RIβ showed the most limited expression pattern in the adrenal gland being 
restricted to the zona reticularis, responsible for sex hormones secretion. Therefore, it could be involved in the 
regulation of these hormones. RIIα was the only subunit that showed expression in all zones of the adrenal cortex 
and additionally in the adrenal medulla, a part of the adrenal gland of neuroendocrine origin that secretes cat-
echolamines. RIIβ, although considered to be one of the main regulatory subunits in the adrenal glands, showed 
only a weak to medium immunoreactivity in the zona fasciculata, which produces mainly cortisol but was abun-
dant in the zona glomerulosa and zona reticularis. Together with the fact that low RIIβ expression is associated 
with an increase in cortisol production in a subset of adrenocortical adenomas, this suggests that at least in the 
adrenal cortex this subunit is responsible for the negative regulation of cortisol production.
In conclusion, our study shows a direct link between PRKACA mutations and reduced protein levels of two 
regulatory subunits of PKA in a sub-group of CPA and that specific expression overlapping the different func-
tional zones of the adrenal cortex, could indicate distinct roles of the different PKA regulatory subunits in the 
secretion of different hormones.
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